ENDRA Life Sciences Inc (NDRA) FinancialsNDRAENDRA Life Sciences Inc

Evaluating the bottom line, ENDRA Life Sciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -152.04%, provide a clear picture of how effectively NDRA converts its operational activities into shareholder value.

In the context of the broader market, NDRA competes directly with industry leaders such as CELZ and NVNO. With a market capitalization of $8.11M, it holds a leading position in the sector. When comparing efficiency, NDRA's gross margin of N/A stands against CELZ's N/A and NVNO's N/A. Such benchmarking helps identify whether ENDRA Life Sciences Inc is trading at a premium or discount relative to its financial performance.

The company's financial performance shows a recent improvement, with a net income of 159,944 USD in Q2 2026, compared to previous quarters of significant losses. This shift indicates potential recovery and operational efficiency.